The massive EPS beat and raised guidance signal accelerating Rare Disease momentum and operational leverage. The $100M buyback adds a capital return catalyst. Watch for continued Cortrophin Gel adoption in acute gouty arthritis and the Phase 4 SYNCHRONICITY trial readout in H2 2026 as next catalysts.
ANIP drugs
ANIP drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 8 $81.86entry
- T+1 · 7mo ago −3.85%α −4.08% · $78.71
- T+5 · 6mo ago −2.79%α −4.25% · $79.58
- T+20 · 6mo ago −0.92%α −0.94% · $81.11
- T+60 · 4mo ago −3.25%α −8.09% · $79.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 consensus by 57.7%, on revenue of $237.5M (20.5% YoY growth), above the $207.6M consensus. The company raised full-year 2026 guidance for revenue to $1.08B-$1.14B and adjusted EPS to $9.19-$9.69, and authorized a $100M share repurchase program. Cortrophin Gel revenue grew 42.1% YoY to $75.1M, and the Rare Disease segment expanded 36.9%.
Key Financial Metrics
Key Facts
- Q1 2026 adjusted non-GAAP diluted EPS of $2.05 vs consensus $1.30 (57.7% beat)
- Q1 2026 total net revenue of $237.5M vs consensus $207.6M (14.4% beat), up 20.5% YoY
- Cortrophin Gel net revenue of $75.1M, up 42.1% YoY
- Raised FY2026 guidance: revenue $1.08B-$1.14B (prev. $1.055B-$1.115B), adjusted EPS $9.19-$9.69 (prev. $8.83-$9.34)
- Board authorized $100M share repurchase program through May 2029
- GAAP net income available to common shareholders of $29.5M ($1.28 diluted EPS) vs $15.3M ($0.69) in prior year
- Adjusted non-GAAP EBITDA of $63.0M, up 24.1% YoY
- Cash flow from operations of $58.4M in Q1; $311.2M unrestricted cash at quarter end
Financial Impact
Q1 revenue beat consensus by ~$29.9M (14.4%); EPS beat by $0.75 (57.7%); FY guidance raised by $25M at midpoint for revenue and $0.36 for adjusted EPS
Risk Factors
- Brands revenue declined 50.9% YoY, indicating normalization in demand for certain products
- Gross margin contracted ~230bps YoY (GAAP) due to higher royalty-bearing product mix
- Dependence on Cortrophin Gel for growth; insurance re-verification seasonality could impact future quarters
- Debt of $625M principal outstanding; interest expense remains a cash flow drag
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290972 |
Track record
34 reports on ANIP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
- Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
- Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
- Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
- Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
- Nov 5, 202617d ago 8-K Bullish 6/10 No price data
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
- Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers